EUVIMEDEUVIMED entdecken
Crossref

Astragaloside IV ameliorates combined allergic rhinitis and asthma syndrome by inhibiting the activation of the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways

Ruizhi Wang, Fan Ye, Yiwen Li, Junhai Chen, He Zhang, Guixian Liang, Min Dai, Qintai Yang, Min Zhou

Naunyn-Schmiedeberg's Archives of Pharmacology · 29.10.2026

DOI: 10.1007/s00210-026-05987-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 29.10.2026. Verfasst von Ruizhi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University, No. 600, Tianhe Road, Tianhe District, Guangz…. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Astragaloside IV (As-IV) has demonstrated therapeutic potential for allergic rhinitis and asthma. However, a systematic investigation is lacking. This study was aimed at systematically elucidating the molecular mechanisms of As-IV in treating combined allergic rhinitis and asthma syndrome (CARAS) through network pharmacology combined with RNA sequencing analysis. A BALB/c mouse model of CARAS was established using ovalbumin. Nasal and bronchopulmonary allergic symptoms were recorded. Histopathological changes in the respiratory tract were assessed via H&E, PAS, and Masson staining. Network pharmacology and lung RNA sequencing were systematically employed to predict potential molecular mechanisms. WB, IF, and IHC were used to validate the activation of the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways, as well as the expression of epithelial barrier and mesenchymal components. Finally, molecular docking and molecular dynamics simulations were performed to evaluate the binding affinity of As-IV with key target proteins. As-IV alleviated allergic symptoms, improved histopathological morphology, and reduced eosinophil and Th2 cell infiltration. Furthermore, As-IV markedly suppressed the activation of STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways, mitigated epithelial barrier damage, and decreased mesenchymal component expression. Molecular docking and molecular dynamics simulations confirmed that As-IV may potentially interact with STAT6 and AKT, suggesting its ability to modulate their conformations and biological activities. As-IV attenuates type 2 inflammation and epithelial barrier injury in the respiratory tract by inhibiting the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways. This study is the first to systematically unravel and validate the molecular mechanisms of As-IV in CARAS through integrated network pharmacology and RNA sequencing analysis, providing a robust scientific basis for its therapeutic application.

Schlagwörter

Stichwörter der Autor:innen

Astragalus mongholicus BungeAKTAstragaloside IVCombined allergic rhinitis and asthma syndromeEpithelial barrierSTAT6

Autor:innen und Institutionen

  • Department of Otolaryngology, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou, 510630, China.
  • Department of Allergy, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University , No. 600, Tianhe Road, Tianhe District, Guangzhou, 510630, China.
  • Key Laboratory of Airway Inflammatory Disease Research and Innovative Technology Translation, Guangzhou, China.
  • Department of Allergy, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University , No. 600, Tianhe Road, Tianhe District, Guangzhou, 510630, China. daimin@mail.sysu.edu.cn.
  • Department of Traditional Chinese Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. daimin@mail.sysu.edu.cn.
  • Department of Otolaryngology, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou, 510630, China. yangqint@mail.sysu.edu.cn.

Zitieren

APA

Wang, R., Ye, F., Li, Y., Chen, J., Zhang, H., Liang, G., Dai, M., Yang, Q., & Zhou, M. (2026). Astragaloside IV ameliorates combined allergic rhinitis and asthma syndrome by inhibiting the activation of the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05987-2

Vancouver

Wang R, Ye F, Li Y, Chen J, Zhang H, Liang G, et al. Astragaloside IV ameliorates combined allergic rhinitis and asthma syndrome by inhibiting the activation of the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05987-2

BibTeX
@article{Wang2026,
  author = {Wang, Ruizhi and Ye, Fan and Li, Yiwen and Chen, Junhai and Zhang, He and Liang, Guixian and Dai, Min and Yang, Qintai and Zhou, Min},
  title = {Astragaloside IV ameliorates combined allergic rhinitis and asthma syndrome by inhibiting the activation of the STAT6/GATA3/IL-4 and PI3K/AKT/NF-κB signaling pathways},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05987-2}
}
Kostenlos starten →